{"id":16015,"date":"2022-02-11T18:57:08","date_gmt":"2022-02-11T13:27:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16015"},"modified":"2022-03-10T10:27:41","modified_gmt":"2022-03-10T04:57:41","slug":"major-pharmaceutical-companies-by-continents","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents","title":{"rendered":"Mapping the Biggest Pharmaceutical Companies by Continents"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1b10663f278\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1b10663f278\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Continent_North_America\" >Continent: North America<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_Johnson_Johnson\" >About Johnson &amp; Johnson<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share\" >Key Products Revenue Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022\" >Pharmaceutical Pipeline 2022<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_AbbVie\" >About AbbVie<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share-2\" >Key Products Revenue Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022-2\" >Pharmaceutical Pipeline 2022<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_Eli_Lilly\" >About Eli Lilly<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share-3\" >Key Products Revenue Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022-3\" >Pharmaceutical Pipeline 2022<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Continent_Europe\" >Continent: Europe<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_Roche\" >About Roche<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share-4\" >Key Products Revenue Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022-4\" >Pharmaceutical Pipeline 2022<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_Novartis\" >About Novartis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share-5\" >Key Products Revenue Share&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022-5\" >Pharmaceutical Pipeline 2022<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Continent_Asia\" >Continent: Asia<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_Astellas_Pharma\" >About Astellas Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share_Upto_Q3\" >Key Products Revenue Share (Upto Q3)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022-6\" >Pharmaceutical Pipeline 2022<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_Takeda_Pharmaceutical_Company\" >About Takeda Pharmaceutical Company<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share_April_%E2%80%93_December_2021\" >Key Products Revenue Share (April &#8211; December 2021)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022-7\" >Pharmaceutical Pipeline 2022<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Continent_Oceania\" >Continent: Oceania<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#About_CSL_Limited\" >About CSL Limited<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Key_Products_Revenue_Share-6\" >Key Products Revenue Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Pharmaceutical_Pipeline_2022-8\" >Pharmaceutical Pipeline 2022<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\/#Way_Ahead\" >Way Ahead<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Today, the most important factor affecting the world\u2019s economy is the Global Pharmaceutical Industry. This industry is at the forefront driving about one trillion dollars annually. Pharmaceutical companies are driving a major share of the global economy with the rapidly advancing technological and scientific base, plus an exponential demand for medicines in the market. It is observed that the American pharmaceutical industry holds up for almost 40% of the revenue. On the other hand, Asia is fastly catching up and high revenues in prescription sales are also seen from the European pharmaceuticals. Just after the COVID-19 pandemic hit the world, the global pharmaceutical industry came in solitude combining efforts from companies from various continents coming together in every possible way. As 2020-21 progressed, <a href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\">revenue shares of major pharmaceuticals &amp; drug makers<\/a> multiplied many folds. Let\u2019s take a look at drug giants classified based on their continents of origin and how they swept the pharmaceutical market in 2021, as well as their revenue shares that surfaced the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-continent-north-america\"><span class=\"ez-toc-section\" id=\"Continent_North_America\"><\/span><strong>Continent: North America<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p id=\"h-company-johnson-johnson\"><strong>Company: Johnson &amp; Johnson<\/strong><\/p>\n\n\n\n<p id=\"h-revenue-in-2021-usd-93-8-billion\"><strong>Revenue in 2021: USD 93.8 billion<\/strong> <\/p>\n\n\n\n<p><strong>Headquarters: New Brunswick, New Jersey, United States &nbsp;&nbsp;<\/strong>          <\/p>\n\n\n\n<p><strong>Founded: 1886<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Johnson_Johnson\"><\/span><strong>About Johnson &amp; Johnson<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Johnson &amp; Johnson (J&amp;J) is an American pharmaceutical company that offers a wide range of products via three key business divisions: <strong>Pharmaceutical, Medical Devices, <\/strong>and <strong>Consumer Health.<\/strong> The key therapeutic areas on which the company focuses through its pharmaceutical division include <strong>immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.<\/strong> Whereas J&amp;J&#8217;s primary medical device emphasis areas are <strong>orthopedics, surgery, interventional solutions (cardiovascular and neurovascular), and eye health.<\/strong> Moreover, its consumer health division is specialized in <strong>skin health\/beauty, over-the-counter pharmaceuticals, infant care, dental care, women&#8217;s health, and wound care for consumer health.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share\"><\/span><strong>Key Products Revenue Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Johnson &amp; Johnson is one of the most profitable pharmaceutical company across the globe. More than <strong>50%<\/strong> of the revenue comes from its pharmaceutical division. In 2021, it generated a revenue of <strong>USD 52 billion <\/strong>through pharmaceutical sales. The rest of the division, i.e. medical devices and consumer health contributed <strong>USD 27 billion<\/strong> and <strong>USD 14.6 billion<\/strong> of revenue respectively.<\/p>\n\n\n\n<p>The pharmaceutical sales across the world were mainly driven by the sales of the company\u2019s lead assets in oncology such as <strong>Darzalex (daratumumab) (USD 6 billion)<\/strong>, a biologic for the treatment of multiple myeloma, and <strong>Imbruvica (ibrutinib) (USD 4.3 billion)<\/strong>, a prescription drug for the treatment of various cancers. In addition, the company\u2019s blockbuster immunological drugs such as <strong>Stelara (ustekinumab) (USD 9.1 billion) and Remicade (infliximab) (USD 3.1 billion)<\/strong> biologics for the treatment of a number of immune-mediated inflammatory and autoimmune diseases also contributed to the revenue. Moreover, Janssen\u2019s <strong>COVID-19 Vaccine (USD 2.3 billion)<\/strong> further adds to the growth of the company.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Johnson &amp; Johnson\u2019s pharmaceutical pipeline is looking promising for the year 2022. The company is looking for potential approval in the US and EU to strengthen its position in the pharmaceutical market. The drugs in the pipeline for potential approval include <strong>Cabenuva<\/strong> (for HIV pediatric), <strong>Carvykti<\/strong> (for relapsed refractory Multiple Myeloma), and <strong>Imbruvica<\/strong> {for Frontline Chronic Lymphocytic Leukemia (I + V fixed duration)}.&nbsp;<\/p>\n\n\n\n<p>Apart from these, there are several other drugs that are in planned submission for US\/EU including <strong>Aprocitentan <\/strong>(difficult to treat Hypertension), <strong>Imbruvica<\/strong> (Treatment na\u00efve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab), <strong>Teclistamab<\/strong> (relapsed refractory Multiple Myeloma), <strong>VAC18193<\/strong> (RSV adult vaccine), and <strong>VAC31518<\/strong> (COVID-19 vaccine).&nbsp;<\/p>\n\n\n\n<p>Furthermore, <strong>Imbruvica, Carvykti, Aprocitentan, Darzalex<\/strong> are in the late stage of development for various indications along with several other drugs. The launch of these drugs will positively impact the growth of the company.<\/p>\n\n\n\n<p id=\"h-company-abbvie\"><strong>Company: AbbVie &nbsp;<\/strong>                            <\/p>\n\n\n\n<p><strong>Revenue in 2021: USD 56.1 billion<\/strong><\/p>\n\n\n\n<p id=\"h-headquarters-north-chicago-illinois-the-united-states\"><strong>Headquarters: North Chicago, Illinois, the United States<\/strong><\/p>\n\n\n\n<p id=\"h-founded-2013\"><strong>Founded: 2013<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_AbbVie\"><\/span><strong>About AbbVie<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>AbbVie is a research-based biopharmaceutical firm that develops and sells pharmaceutical products. It focuses on chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including Blood Cancers, virology, including Hepatitis C Virus and Human Immunodeficiency Virus (HIV), neurological disorders, such as Parkinson&#8217;s Disease, metabolic diseases, including Thyroid Disease and complications associated with Cystic Fibrosis, pain associated with Endometriosis, and other serious health conditions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-products-revenue-share\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share-2\"><\/span><strong>Key Products Revenue Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The company manufactures around 30 products but mainly depends on its immunological sector. Last year, the immunological sector grabbed a revenue of <strong>USD 25.2 billion.<\/strong> Several of AbbVie\u2019s drugs generate billions of dollars in revenue each year. But <a href=\"https:\/\/www.delveinsight.com\/report-store\/adalimumab-biosimilars-insight\"><strong>Humira (adalimumab)<\/strong><\/a> is by far <strong>AbbVie&#8217;s <\/strong>greatest revenue source. With the best-selling drug Humira under its roof, the firm has had a monopoly in the pharmaceutical drug market for a long time.&nbsp;<\/p>\n\n\n\n<p><strong>Humira (adalimumab)<\/strong> is approved for the treatment of adults with moderate to severely active <strong>Rheumatoid Arthritis,<\/strong> severe active <strong>Ankylosing Spondylitis,<\/strong> severe<strong> Axial Spondyloarthritis<\/strong> without radiographic evidence of AS, moderate to <strong>Severe Chronic Plaque Psoriasis, <\/strong>active and progressive <strong>Psoriatic Arthritis,<\/strong> moderately to severely active<strong> Crohn&#8217;s Disease,<\/strong> moderately to severely active <strong>Ulcerative Colitis,<\/strong> moderately to severely active<strong> Hidradenitis Suppurativa,<\/strong> and <strong>non-infectious intermediate, posterior<\/strong> and <strong>Panuveitis <\/strong>in adults. In addition, <strong>Humira <\/strong>is also approved for pediatric patients suffering from active enthesitis-related <strong>Arthritis<\/strong>, severe <strong>Chronic Plaque Psoriasis<\/strong>, moderately to severely active <strong>Crohn&#8217;s disease<\/strong>, and active<strong> Polyarticular Juvenile Idiopathic Arthritis.<\/strong><\/p>\n\n\n\n<p>In 2021, the company generated a whopping amount, <strong>USD 20.6 billion<\/strong> alone, by the sales of Humira. The other immunological drugs, <strong>Skyrizi<\/strong> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/upadacitinib-drug-insight-and-market\"><strong>Rinvoq<\/strong><\/a> generated only <strong>USD 2.9 billion<\/strong> and <strong>USD 1.6 billion<\/strong> in revenue through their sales, respectively. Apart from Humira, the company\u2019s best-selling drug is <strong>Imbruvica<\/strong>. Imbruvica collected a sum of <strong>USD 5.4 billion<\/strong> through its sale. The other drug from the same sector, <strong>Venclexta <\/strong>generated revenue of only <strong>USD 1.8 billion.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022-2\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>AbbVie has a strong pipeline with more than <strong>50 drugs<\/strong> in various stages of development, with a focus on oncology and immunology. However, as the Humira patent expiration date approaches, AbbVie is speeding up the trials of its other lead assets. AbbVie key drugs, including <strong>Rinvoq, Navitoclax, Imbruvica, Venclexta, <\/strong>and<strong> Skyrizi,<\/strong> are in the late stage of development for various indications. Their approval will give AbbVie a boost in the pharmaceutical market as they are already approved for several indications. Apart from these, AbbVie is also evaluating other drugs from various therapeutic areas that will join the respective market soon.<\/p>\n\n\n\n<p id=\"h-company-eli-lilly-and-company\"><strong>Company: Eli Lilly and Company &nbsp; &nbsp; &nbsp; &nbsp;<\/strong>       <\/p>\n\n\n\n<p><strong>Revenue in 2021: USD 28.3 billion<\/strong><\/p>\n\n\n\n<p id=\"h-headquarters-indianapolis-indiana-the-united-states\"><strong>Headquarters: Indianapolis, Indiana, the United States<\/strong><\/p>\n\n\n\n<p id=\"h-founded-1876\"><strong>Founded: 1876<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-eli-lilly\"><span class=\"ez-toc-section\" id=\"About_Eli_Lilly\"><\/span><strong>About Eli Lilly<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Eli Lilly and Company is a pharmaceutical company. The company is involved in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. The key focus areas of the company include Alzheimer\u2019s, COVID-19, Cancer, Diabetes, Immunology, and Pain. The lead assets of the company include its diabetic drugs <a href=\"https:\/\/www.delveinsight.com\/report-store\/humalog-api-insights\"><strong>Humalog<\/strong><\/a><strong>, Humulin,<\/strong> <strong>Jardiance<\/strong>, and <strong>Trulicity<\/strong>, its oncologic drugs <strong>Cyramza<\/strong>, <strong>Retevmo<\/strong>, <strong>Tyvyt<\/strong>, and <strong>Verzenio<\/strong>, its immunological drugs <strong>Olumiant <\/strong>and <strong>Taltz, <\/strong>and its neuroscience drug <strong>Emgality<\/strong>. The other therapies from the company\u2019s portfolio include <strong>Bamlanivimab, etesevimab, Cialis, and <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/forteo-api-insights\"><strong>Forteo<\/strong><\/a><strong>.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-products-revenue-share-1\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share-3\"><\/span><strong>Key Products Revenue Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The diabetes sector is among the most prominent sector for the company with respect to pharmaceutical market growth. The majority of revenue comes from the sales of diabetic drugs. In 2021, the diabetic sector of Eli Lilly grabbed a revenue of <strong>USD 12.5 billion.<\/strong> The major chunk of it was grabbed by its lead assets Trulicity. <strong>Trulicity<\/strong> made a sale of <strong>USD 6.4 billion <\/strong>across the world due to its increased demand. Another drug from the same segment that contributed to the growth is Jardiance. <a href=\"https:\/\/www.delveinsight.com\/report-store\/jardiance-api-insights\"><strong>Jardiance<\/strong><\/a><strong> <\/strong>is a part of <strong>Eli Lilly\u2019s<\/strong> and <strong>Boehringer Ingelheim\u2019s<\/strong> collaboration. It collected an amount of <strong>USD 1.4 billion<\/strong> through its worldwide sales. Furthermore, several of Eli Lilly\u2019s diabetic drugs, including <strong>Humalog, Humulin, and Basaglar<\/strong> didn\u2019t perform well and there was a drop in sales of these drugs mainly due to lower realized prices.<\/p>\n\n\n\n<p>Apart from diabetic drugs, the company\u2019s oncological and immunological drugs were the second and third best-seller drugs. Together they constituted a revenue of <strong>USD 8.3 billion<\/strong>. In addition, its COVID-19 antibodies, including the sales of <strong>bamlanivimab, <\/strong>generated a revenue of <strong>USD 2.2 billion,<\/strong> whereas <strong>Forteo <\/strong>contributed <strong>USD 801.9 million<\/strong> to the company&#8217;s growth.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022-3\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Eli Lilly\u2019s pharmaceutical pipeline landscape is completely packed for 2022, with a number of drugs in the late stages of development. Eli Lilly evaluates its key drugs such as <strong>Jardiance, Emgality, Olimiant, Retevmo, and Tyvyt <\/strong>in various indications for regulatory submissions and actions. Apart from these, the company is also testing some novel drug candidates, including <strong>Donanemab and Pirtobrutinib,<\/strong> for regulatory submissions.<\/p>\n\n\n\n<p>Furthermore, Eli Lilly is also planning to announce the positive results from the Phase 3 studies of some of the drugs and initiate Phase 3 clinical trials of around 9 drugs. If everything goes well for the company, then it will make a huge profit from the last year.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"548\" height=\"566\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194706\/Biggest-Pharma-Companies-by-Continents-1.png\" alt=\"pharma-companies-by-continents\" class=\"wp-image-16097\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194706\/Biggest-Pharma-Companies-by-Continents-1.png 548w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194706\/Biggest-Pharma-Companies-by-Continents-1-290x300.png 290w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194706\/Biggest-Pharma-Companies-by-Continents-1-145x150.png 145w\" sizes=\"(max-width: 548px) 100vw, 548px\" \/><figcaption><strong>Biggest Pharmaceutical Companies by Continents<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-continent-europe\"><span class=\"ez-toc-section\" id=\"Continent_Europe\"><\/span><strong>Continent: Europe<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p id=\"h-company-f-hoffmann-la-roche-ag-roche\"><strong>Company: F. Hoffmann-La Roche AG (Roche)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;                           <\/strong><\/p>\n\n\n\n<p><strong>Revenue in 2021: USD 67.9 billion<\/strong><\/p>\n\n\n\n<p><strong>Headquarters: Basel, Switzerland<\/strong><\/p>\n\n\n\n<p><strong>Founded: 1896<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Roche\"><\/span><strong>About Roche<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>F. Hoffmann-La Roche AG, commonly referred to as Roche worldwide is a Swiss multinational healthcare company operating around the world. The company\u2019s key operations are divided into two categories &#8211; <strong>Pharmaceuticals <\/strong>and <strong>Diagnostics<\/strong>. F. Hoffmann-La Roche is a full-time associate of the <strong>European Federation of Pharmaceutical Industries and Associations (EFPIA). <\/strong>The company when founded in the year 1896, mainly focused on producing several vitamin preparations. Roche excels in almost every field of pharmaceuticals, whether it is <strong>cancer <\/strong>treatment, treatment against<strong> viral diseases,<\/strong> or even for treatment of <strong>metabolic diseases.<\/strong> It is evaluated that Roche holds the world&#8217;s biggest expenditures in the pharmaceutical R&amp;D sector. On the other hand, Roche Diagnostics&#8217; focal point is the manufacturing of diagnostic equipment and reagents. The diagnostic equipment is used for medical diagnostic applications and several other types of research. Roche Professional Diagnostics is located in Rotkreuz, Switzerland.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-products-revenue-share-2\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share-4\"><\/span><strong>Key Products Revenue Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Currently, there are almost <strong>100+ marketed drugs<\/strong> being manufactured and sold by Roche. These drugs occupy a major pharmaceuticals market share i.e. around a jaw-dropping <strong>USD 48.6 billion <\/strong>in terms of sales revenue. Their pharmaceutical segment covers <strong>oncology (USD 22 billion)<\/strong>, <strong>immunology (USD 9 billion)<\/strong>, <strong>neuroscience (USD 6.7 billion)<\/strong>, <strong>hemophilia A<\/strong> <strong>(USD 3.26 billion)<\/strong>, <strong>ophthalmology (USD 1.46 billion)<\/strong>,&nbsp; and other<strong> infectious diseases (USD 3.6 billion)<\/strong>,&nbsp; based drugs. The oncology bestsellers included <strong>Perjeta, Tecentriq, <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/bevacizumab-biosimilars-insight\"><strong>Avastin<\/strong><\/a><strong>, Herceptin, <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/rituximab-biosimilars-insight\"><strong>Rituxan<\/strong><\/a><strong>, <\/strong>and others. Immunology drugs include names such as <strong>Actemra, Xolair, Esbriet,<\/strong> neuroscience drugs <strong>Ocrevus, Evrysdi,<\/strong> single but mega-blockbuster <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-a-pipeline-insight-2020\">Hemophilia A drug<\/a>, <strong>Hemlibra<\/strong>, whereas other infectious diseases included drugs such as <strong>Ronapreve, Rocephin,<\/strong> and others. The growing demand for new medicines, including <strong>Hemlibra, Ocrevus, Tecentriq, Evrysdi, Phesgo <\/strong>also served as a driving factor for Roche\u2019s therapeutics demand in the pharmaceuticals market.<\/p>\n\n\n\n<p>The Diagnostics Division reported annual sales of<strong> USD 19.2 billion <\/strong>in 2021. It comprised <strong>Core Lab (USD 8 billion), Molecular Lab (USD 5.2 billion), Point of Care Lab&nbsp; (USD 2.7 billion), Diabetes Care (USD 1.8 billion), and Pathology Labs (USD 1.3 billion). <\/strong>The growth in diagnostic equipment is mainly due to sales of <a href=\"https:\/\/www.delveinsight.com\/covid19\"><strong>COVID-19-related products<\/strong><\/a>, most notably <strong>&nbsp;SARS-CoV-2 PCR test <\/strong>and the <strong>SARS-CoV-2 Rapid Antigen test Routine testing,<\/strong> which was greatly affected by the pandemic during 2020, rebounded across all regions in 2021. As a direct result, sales grew in all the mainland regions &#8211; Europe, Middle East, and Africa region as well as Asia-Pacific region.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceutical-pipeline-2022\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022-4\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>An extremely vigorous novel therapeutic pipeline with <strong>80+ new molecular entities<\/strong> in Roche\u2019s pipeline covers a broad range of diseases, therapeutic areas with highly innovative technologies incorporated in research. These are applied in order to create and produce active molecules involved in drug making. Currently, in Roche\u2019s pipeline, there are <strong>45 drugs<\/strong> in <strong>Phase I <\/strong>clinical trials, <strong>21 drugs<\/strong> in <strong>Phase II <\/strong>clinical trials,<strong> 11 drugs<\/strong> in<strong> Phase III <\/strong>clinical trials, and<strong> 3 drugs<\/strong> under <strong>registration. <\/strong>The clinical pipeline includes therapeutic areas such as <strong>Oncology, Inflammation\/Immunology, Neuroscience, Infectious diseases, Ophthalmology, Metabolics, <\/strong>and several others.<\/p>\n\n\n\n<p><strong>Company: Novartis International AG&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Revenue in 2021: USD 51.6 billion<\/strong><\/p>\n\n\n\n<p><strong>Headquarters: Basel, Switzerland&nbsp; &nbsp; &nbsp; &nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Founded:  1996<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Novartis\"><\/span><strong>About Novartis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Novartis International AG is often considered to be one of the largest pharmaceutical companies in the world. A Swiss multinational pharmaceutical corporation, it is based in Basel, Switzerland. In the year 1996, two Swiss companies namely <strong>Sandoz <\/strong>and <strong>Ciba-Geigy <\/strong>merged to form Novartis. It is a leading medicines and drugs company globally, where innovations, recent scientific research, and digital technologies are combined together to give rise to transformative treatments in therapeutic areas of great medical need. Novartis is a full member of the<strong> International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA),<\/strong> and the<strong> Pharmaceutical Research and Manufacturers of America (PhRMA).<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-products-revenue-share-3\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share-5\"><\/span><strong>Key Products Revenue Share&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Novartis has been a key player in the development of many blockbuster drugs that created huge revenues for the company. They are constantly manufacturing, marketing, and distributing almost <strong>103 drugs<\/strong> in the pharmaceutical market. <strong>Cosentyx <\/strong>dealing with <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-market\">Psoriasis treatment<\/a> turned out to be the drug giant\u2019s best-selling pharmaceutical drug in the year 2021 with <strong>USD 4.7 billion<\/strong> of sales generated. The second best-seller and third best-seller drugs were <a href=\"https:\/\/www.delveinsight.com\/report-store\/entresto-api-insights\"><strong>Entresto<\/strong><\/a> (fixed-dose combination used in heart failure) and <strong>Gilenya <\/strong>(immunomodulating medication for <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">Multiple Sclerosis treatment<\/a>) generating revenues of <strong>USD 3.5 billion <\/strong>and <strong>USD 2.7 billion<\/strong> respectively. Whereas <strong>Tasigna<\/strong> (Chronic Myelogenous Leukemia treatment) and <strong>Promacta<\/strong> (medication used to treat thrombocytopenia and severe aplastic anemia) generated a revenue of <strong>USD 2 billion <\/strong>each.<\/p>\n\n\n\n<p>Novartis has many recent FDA approvals such as on<strong> October 29, 2021, Scemblix<\/strong> for patients with Philadelphia chromosome-positive chronic myeloid leukemia, and then on<strong> 22nd December 2021, Leqvio, <\/strong>a first-in-class siRNA to lower cholesterol was FDA approved. Many more product launches are going to help strengthen the pharmaceutical market for Novartis in the coming years<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceutical-pipeline-2022-1\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022-5\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Currently, the Novartis pipeline is sufficiently loaded with almost <strong>150+ R&amp;D projects <\/strong>and one-third of the Novartis total pipeline projects targets for priority diseases area which include <strong>60+ drugs<\/strong>. These pipeline projects targeting priority diseases constitute<strong> malaria (9 projects), COVID-19 (5), asthma (4) <\/strong>and <strong>oncology (23),<\/strong> and others. There are <strong>43 <\/strong>pipeline therapies in <strong>Phase I<\/strong> clinical trials, <strong>64 <\/strong>pipeline therapies in <strong>Phase II<\/strong> clinical trials, and <strong>54 <\/strong>pipeline therapies in ongoing <strong>Phase III<\/strong> clinical trials. The robust pipeline constitutes for drugs like<strong> CNP 520<\/strong> for Alzheimer\u2019s Disease,<strong> KAE 609, KAF 156 <\/strong>for Malaria, <strong>QBW 251<\/strong> for Cystic Fibrosis, <strong>ZPL 389<\/strong> for Atopic Dermatitis, <strong>Rydapt <\/strong>for Acute Myeloid Leukemia, and many others.<\/p>\n\n\n\n<p><strong>Read our blog to find out <\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\"><strong>Which Pharma Company Tops the Chart in 2020<\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-continent-asia\"><span class=\"ez-toc-section\" id=\"Continent_Asia\"><\/span><strong>Continent: Asia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Company: Astellas Pharma &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <\/strong><\/p>\n\n\n\n<p><strong>Revenue in 2021: USD 8.6 billion (Upto Q3, 2021)<\/strong><\/p>\n\n\n\n<p><strong>Headquarters: Chuo City, Tokyo, Japan<\/strong><\/p>\n\n\n\n<p><strong>Founded: 2005<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-astellas-pharma\"><span class=\"ez-toc-section\" id=\"About_Astellas_Pharma\"><\/span><strong>About Astellas Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A Japanese multinational pharmaceutical company, Astellas was founded in the year 2005. It was established by merging the former Yamanouchi Pharmaceutical Co., Ltd. and the former Fujisawa Pharmaceutical Co., Ltd., Headquartered in Tokyo. It is considered to be one of the biggest Asian pharmaceutical firms. Astellas is dedicated to improve healthcare across the world by providing reliable and innovative pharmaceutical products. Astellas\u2019 main priority areas of interest in the R&amp;D involve <strong>diabetes, infectious diseases, oncology, gastrointestinal diseases, <\/strong>and <strong>central nervous system diseases. <\/strong>Astellas&#8217; franchise areas constitute<strong> immunology (transplantation), urology, cardiology, <\/strong>and <strong>infectious diseases.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-products-revenue-share-upto-q3\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share_Upto_Q3\"><\/span><strong>Key Products Revenue Share (Upto Q3)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Astellas is currently selling its products in almost <strong>70+ countries<\/strong> and <strong>territories <\/strong>worldwide. On top of that, their sales ratio is <strong>80% overseas (other than Japan).<\/strong> Astellas is doing wonders if the oncology drug sector is taken under consideration. Their main products generating huge revenues for the company are mostly oncology drugs.&nbsp;<\/p>\n\n\n\n<p>The key products for sales include the drug <a href=\"https:\/\/www.delveinsight.com\/report-store\/xtandi-drug-insight-and-market-forecast\"><strong>Xtandi<\/strong><\/a>, a major blockbuster drug that generated a revenue of jaw-dropping <strong>USD 3.5 billion<\/strong> in the first 9 months of 2021. This drug focuses on prostate cancer therapeutic area (the leading cause of cancer in men), also it is sold in collaboration with another pharma giant <strong>Pfizer<\/strong>. The next drug to grab a substantial market share was <strong>Xospata<\/strong>, an anti-cancer drug that is a tyrosine kinase inhibitor. <strong>Xospata <\/strong>generated <strong>USD 222 million<\/strong>. Another cancer drug &#8211; <strong>Padcev <\/strong>for bladder cancer treatment, an <a href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\">antibody-drug conjugate (ADC)<\/a>, brought about <strong>USD 126 million<\/strong> from around the world.<\/p>\n\n\n\n<p>On the other hand, Astellas&#8217; different therapeutic area drugs also thrived including <strong>Myrbetriq <\/strong>used for overactive bladder treatment, gaining a gigantic <strong>USD 1 billion<\/strong> revenue for the first 3 quarters in 2021. In addition to that, <strong>Prograf <\/strong>(includes Advagraf, Graceptor, and ASTAGRAF XL) for prevention of post-transplant organ rejection claimed to acquire sales of a whopping <strong>1.2 billion USD.<\/strong> It is an immunosuppressive drug, to lower the risk of organ rejection after allogeneic organ transplantation. Lastly, <strong>Evrenzo <\/strong>seems to have occupied <strong>18 million USD<\/strong> for anemia treatment.<\/p>\n\n\n\n<p><strong>Company: Takeda Pharmaceutical Company Limited&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Revenue in 2021: 29.5 billion USD&nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Headquarters: Nihonbashi, Chuo, Tokyo, Japan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Founded: 1781<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceutical-pipeline-2022-2\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022-6\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A robust Astellas Pipeline constitutes about <strong>25+ pipeline therapies<\/strong> in different developmental stages aiming to target several classes of diseases. These include Immuno-oncology drugs &#8211; <strong>ASP1951, ASP7517, ASP0739<\/strong>, and many others, ophthalmology pipeline drug &#8211; <strong>ASP7317<\/strong> for blindness and regeneration, genetic regulation pipeline drugs &#8211; <strong>AT132, AT845,<\/strong> and many others for different target areas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-takeda-pharmaceutical-company\"><span class=\"ez-toc-section\" id=\"About_Takeda_Pharmaceutical_Company\"><\/span><strong>About Takeda Pharmaceutical Company<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Takeda Pharmaceutical Company is the largest pharmaceutical company in Asia. It was founded in the year <strong>1781 <\/strong>and was incorporated on<strong> January 29, 1925. <\/strong>The company focuses on <strong>gastroenterology, metabolic disorders, inflammation, neurology,<\/strong> and <strong>oncology <\/strong>via its independent subsidiary,<strong> Takeda Oncology.<\/strong> Takeda can be considered as a research-based global company that pivots around innovations in drugs and medicines. The main focus of this company revolves around pharmaceutical drugs only. Being the largest Asian pharmaceutical firm, it is also a global pioneer of the Healthcare Industry.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-products-revenue-share-april-december-2021\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share_April_%E2%80%93_December_2021\"><\/span><strong>Key Products Revenue Share (April &#8211; December 2021)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Being one of the most profitable pharmaceutical companies in the world, Takeda has over <strong>54 marketed drugs<\/strong> which generate a tremendous amount of revenue for the drug giant. Total <strong>Gastroenterology <\/strong>drugs provided a massive revenue of <strong>USD 5.8 billion<\/strong>, which includes the company\u2019s most successful gut selective, major blockbuster drug &#8211; <strong>Entyvio,<\/strong> <strong>Takecab-F, Gattex, Dexilant, Pantoloc, <\/strong>and others. <strong>Plasma Derived Therapy (PDT) Immunology<\/strong> is another therapeutic area driving mass sales accumulating <strong>USD 3.2 billion, <\/strong>constituting only two hit drugs, <strong>Immunoglobulin<\/strong> and <strong>Albumin<\/strong>. In addition to that, <strong>Rare diseases <\/strong>therapeutic area which has drugs like<strong> Elaprase, Replagal, Vpriv, Natpar<\/strong> and rare <strong>Hematology <\/strong>drugs such as <strong>Advate, Adynovate, Feiba, Recombinate<\/strong> altogether account for <strong>USD 4 billion<\/strong> of sales. Furthermore, superhit <strong>Oncology <\/strong>drugs like <strong>Velcade, Leuplin, Ninlaro, Adcetris, <\/strong>and others plus <strong>Neurology <\/strong>drugs such as <strong>Vyvanse <\/strong>(best seller neurology), <strong>Trintellix, Intuniv,<\/strong> and others serve for<strong> USD 3.1 billion each.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceutical-pipeline-2022-3\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022-7\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Takeda oncology has almost 20+ oncology pipeline therapies that are under different phases of development, it constitutes drugs in <strong>Phase III <\/strong>clinical trials such as <strong>Brigatinib, Cabozantinib, Ponatinib, Relugolix,<\/strong> and others. In <strong>Phase II <\/strong>clinical trial is<strong> Pevonedistat, <\/strong>whereas in<strong> Phase I\/II <\/strong>there are&nbsp; <strong>Modakafusp Alfa, Subasumstat, TAK-007, TAK-605, TAK-186,<\/strong> and many other oncology drugs. Lastly, in <strong>Phase I <\/strong>clinical trial, drugs like<strong> TAK-500, TAK-940,<\/strong> and others are under investigation.<\/p>\n\n\n\n<p>Takeda\u2019s pipeline therapies deal with other therapeutics fields as well constituting <strong>Rare Genetics &amp; Hematology<\/strong> investigational drugs such as <strong>Takhzyro, Vonvendi, Adynovate, <\/strong>and more. <strong>Gastroenterology <\/strong>drugs such as <strong>Vocinti, Alofisel, PDT<\/strong> investigational drugs such as <strong>Cuvitru, Hyqvia, <\/strong>and others are in Takeda\u2019s therapeutic pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-continent-oceania\"><span class=\"ez-toc-section\" id=\"Continent_Oceania\"><\/span><strong>Continent: Oceania<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p id=\"h-company-csl-limited\"><strong>Company: CSL Limited&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <\/strong><\/p>\n\n\n\n<p><strong>Revenue in 2021: USD 10.3 billion<\/strong><\/p>\n\n\n\n<p id=\"h-headquarters-melbourne-australia\"><strong>Headquarters: Melbourne, Australia&nbsp; &nbsp;<\/strong><\/p>\n\n\n\n<p id=\"h-founded-1916\"><strong>Founded: 1916<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-csl-limited\"><span class=\"ez-toc-section\" id=\"About_CSL_Limited\"><\/span><strong>About CSL Limited<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>CSL Limited develops, manufactures, and sells human pharmaceutical and diagnostic products derived from human plasma. <strong>Pediatric <\/strong>and <strong>adult vaccines, infection, pain medicine, skin disorder treatments, antivenoms, anticoagulants, <\/strong>and <strong>immunoglobulins<\/strong> are among the products offered by the company. The company operates through 2 business units namely, <strong>CSL Behring <\/strong>and <strong>Seqirus.&nbsp;<\/strong><\/p>\n\n\n\n<p>CSL Behring unit mainly develops or manufactures therapies to treat hemophilia, critical care products for shock in trauma treatment, immunoglobulins for infection treatment, and autoimmune diseases. On the other hand, the Seqirus unit produces and distributes biotherapeutic products for the treatment and prevention of serious human medical conditions, such as influenza vaccines, prescription medicines, anti-venoms, and in-licensed pharmaceuticals.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-products-revenue-share-4\"><span class=\"ez-toc-section\" id=\"Key_Products_Revenue_Share-6\"><\/span><strong>Key Products Revenue Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The company\u2019s main source of revenue is from its CSL Behring unit. More than <strong>80% (USD 8.5 billion)<\/strong> of the total revenue came from this unit in 2021. The immunoglobulin products contributed the maximum revenue of <strong>USD 4.2 billion<\/strong> to this led by <strong>Hizentra<\/strong>. Hizentra sales increased by <strong>15%<\/strong>, owing to the increased preference for and patient benefits of home administration, as well as continued uptake for Chronic Inflammatory Demyelinating Polyneuropathy treatment.<\/p>\n\n\n\n<p>Moreover, specialty products made sales of <strong>USD 1.7 billion<\/strong> led by increasing demand for <strong>Haegarda <\/strong>(for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks) and <strong>Kcentra <\/strong>(for urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist). In addition, hemophilia products contributed <strong>USD 1.1 billion<\/strong> through their sales across the world led by key drug <strong>Idelvion <\/strong>(for Hemophilia B).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharmaceutical-pipeline-2022-4\"><span class=\"ez-toc-section\" id=\"Pharmaceutical_Pipeline_2022-8\"><\/span><strong>Pharmaceutical Pipeline 2022<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>CSL through its CSL Behring unit will continue to broaden the geography and develop novel drugs for rare and specialty diseases around the world in our immunology, hematology, and respiratory therapeutic areas. Currently, the company is evaluating <strong>Haegarda, Hizentra, Idelvion,<\/strong> and many more in the late stages for various indications. Apart from these, around 10 drugs are in the early stage of development. The company is planning to launch its late-stage products in the pharmaceutical drug market soon to solve the problem of many people suffering from rare diseases.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/market-intelligence-for-pharmaceutical-innovation\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence-1024x256.png\" alt=\"market-intelligence-in-pharmaceutical-innovation\" class=\"wp-image-16098\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194750\/Market-Intelligence.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-way-ahead\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In 2020, the global impact of the Covid-19 pandemic was unprecedented. But the pharmaceutical industry found the solution and fought back against the virus. There are several pharmaceutical and biotech companies in the healthcare market; some are established players dominating the <a href=\"https:\/\/www.delveinsight.com\/blog\/leading-pharmaceutical-markets-worldwide\">pharmaceutical drug market<\/a>, while many more are still emerging. Countries such as <strong>Brazil, India, Egypt, Russia, <\/strong>and <strong>Columbia<\/strong> are among the emerging healthcare countries. Furthermore, collaborations and mergers will give these pharmaceutical companies a boost in their growth. Moreover, with rising demand for effective and standard healthcare, rising healthcare expenditure, and a growing focus of global organizations on providing better healthcare services to the masses, pharmaceutical and biotech companies are expected to thrive and provide better therapies in the coming years.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Today, the most important factor affecting the world\u2019s economy is the Global Pharmaceutical Industry. This industry is at the forefront driving about one trillion dollars annually. Pharmaceutical companies are driving a major share of the global economy with the rapidly advancing technological and scientific base, plus an exponential demand for medicines in the market. It [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":16100,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[469,706,749],"industry":[17226,17225],"therapeutic_areas":[17242,17233,17227,17245,17228,17234],"class_list":["post-16015","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-pharmaceutical-companies","tag-pharmaceutical-industry","tag-pharmaceutical-market","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-hematological-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Analyzing the Biggest Pharmaceutical Companies by the Continents<\/title>\n<meta name=\"description\" content=\"There are a plethora of successful pharmaceutical and MedTech companies from Johnson &amp; Johnson to CSL Limited across the continents\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Analyzing the Biggest Pharmaceutical Companies by the Continents\" \/>\n<meta property=\"og:description\" content=\"There are a plethora of successful pharmaceutical and MedTech companies from Johnson &amp; Johnson to CSL Limited across the continents\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-11T13:27:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T04:57:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194944\/major-pharmaceutical-companies-by-continents.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Analyzing the Biggest Pharmaceutical Companies by the Continents","description":"There are a plethora of successful pharmaceutical and MedTech companies from Johnson & Johnson to CSL Limited across the continents","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents","og_locale":"en_US","og_type":"article","og_title":"Analyzing the Biggest Pharmaceutical Companies by the Continents","og_description":"There are a plethora of successful pharmaceutical and MedTech companies from Johnson & Johnson to CSL Limited across the continents","og_url":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-02-11T13:27:08+00:00","article_modified_time":"2022-03-10T04:57:41+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194944\/major-pharmaceutical-companies-by-continents.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents","url":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents","name":"Analyzing the Biggest Pharmaceutical Companies by the Continents","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194944\/major-pharmaceutical-companies-by-continents.png","datePublished":"2022-02-11T13:27:08+00:00","dateModified":"2022-03-10T04:57:41+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"There are a plethora of successful pharmaceutical and MedTech companies from Johnson & Johnson to CSL Limited across the continents","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/major-pharmaceutical-companies-by-continents#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194944\/major-pharmaceutical-companies-by-continents.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194944\/major-pharmaceutical-companies-by-continents.png","width":772,"height":482,"caption":"major-pharmaceutical-companies-by-continents"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/11194944\/major-pharmaceutical-companies-by-continents-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Pharmaceutical companies<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Feb 11, 2022","modified":"Updated on Mar 10, 2022"},"absolute_dates_time":{"created":"Posted on Feb 11, 2022 6:57 pm","modified":"Updated on Mar 10, 2022 10:27 am"},"featured_img_caption":"major-pharmaceutical-companies-by-continents","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16015"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16015\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16100"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16015"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16015"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}